Home  |  Contact

UniProtKB/Swiss-Prot O43612: Variant p.Leu16Arg

Orexin
Gene: HCRT
Variant information

Variant position:  16
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Leucine (L) to Arginine (R) at position 16 (L16R, p.Leu16Arg).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and hydrophobic (L) to large size and basic (R)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In NRCLP1; early-onset; impaired trafficking and processing.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  16
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  131
The length of the canonical sequence.

Location on the sequence:   MNLPSTKVSWAAVTL  L LLLLLLPPALLSSGAAAQPL
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         MNLPSTKVSWAAVTLLLLLLLLPPALLSSGAAAQPL

                              MNPPSTKVPWAAVTL-LLLLLLPPALLSPGAAAQPL

Mouse                         MNFPSTKVPWAAVTL-LLLLLLPPALLSLGVDAQPL

Rat                           MNLPSTKVPWAAVTL-LLLLLLPPALLSLGVDAQPL

Pig                           MNPPFAKVSWATVTLLLLLLLLPPAVLSPGAAAQPL

Bovine                        ---------------------------------QPL

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Signal peptide 1 – 33
Modified residue 34 – 34 Pyrrolidone carboxylic acid


Literature citations

A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.
Peyron C.; Faraco J.; Rogers W.; Ripley B.; Overeem S.; Charnay Y.; Nevsimalova S.; Aldrich M.; Reynolds D.; Albin R.; Li R.; Hungs M.; Pedrazzoli M.; Padigaru M.; Kucherlapati M.; Fan J.; Maki R.; Lammers G.J.; Bouras C.; Kucherlapati R.; Nishino S.; Mignot E.;
Nat. Med. 6:991-997(2000)
Cited for: CHARACTERIZATION OF VARIANT NRCLP1 ARG-16; INVOLVEMENT IN NRCLP1;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.